Sagent raises $30 million
This article was originally published in Scrip
Sagent Pharmaceuticals has closed a $30 million extension of last year's $53 million series A financing, led by Vivo Ventures. Jeffrey Gordon, CEO, founder and board chairman, said the money would be used to advance additional products to market, as well as funding product development activities and business initiatives. In May, Sagent bought Spectrum Pharmaceuticals' US ANDA for ondansetron, for the treatment of nausea and vomiting, and the antineoplastics carboplatin, fludarabine and mitoxantrone (Scrip Online, May 14th, 2008). Privately held Sagent was founded in 2006 and has more than 200 products in development.